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Abstract
Background: Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a severely debilitating disease of unknown
pathogenesis consisting of a variety of symptoms including severe fatigue. The objective of the study was to examine the
efficacy and safety of a TLR-3 agonist, rintatolimod (Poly I: C12U), in patients with debilitating CFS/ME.
Methods and Findings: A Phase III prospective, double-blind, randomized, placebo-controlled trial comparing twice weekly
IV rintatolimod versus placebo was conducted in 234 subjects with long-standing, debilitating CFS/ME at 12 sites. The
primary endpoint was the intra-patient change from baseline at Week 40 in exercise tolerance (ET). Secondary endpoints
included concomitant drug usage, the Karnofsky Performance Score (KPS), Activities of Daily Living (ADL), and Vitality Score
(SF 36). Subjects receiving rintatolimod for 40 weeks improved intra-patient placebo-adjusted ET 21.3% (p=0.047) from
baseline in an intention-to-treat analysis. Correction for subjects with reduced dosing compliance increased placebo-
adjusted ET improvement to 28% (p=0.022). The improvement observed represents approximately twice the minimum
considered medically significant by regulatory agencies. The rintatolimod cohort vs. placebo also reduced dependence on
drugs commonly used by patients in an attempt to alleviate the symptoms of CFS/ME (p=0.048). Placebo subjects crossed-
over to receive rintatolimod demonstrated an intra-patient improvement in ET performance at 24 weeks of 39% (p=0.04).
Rintatolimod at 400 mg twice weekly was generally well-tolerated.
Conclusions/Significance: Rintatolimod produced objective improvement in ET and a reduction in CFS/ME related
concomitant medication usage as well as other secondary outcomes.
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Introduction
Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)
is a debilitating disorder characterized by disabling fatigue and a
combination of flu-like symptoms [1–4]. The fatigue is not improved
by bed rest and may be worsened by physical activity. The Centers
for Disease Control and Prevention (CDC) has identified CFS/ME
as an economically and emotionally devastating illness whose
functional impairment can be equivalent to multiple sclerosis, heart
disease, chronic obstructive pulmonary disease, or end-stage renal
disease [4]. The etiologic basis for CFS/ME is unknown and may be
multifactorial with a variety of viruses and immunological
abnormalities linked to its pathogenesis [5–8] that may be familial
[7] and dependent on recently discovered genetic signatures [9,10].
CFS/ME is estimated to occur in at least 1 million individuals in
the US, occurs most often in persons 40 to 59 years of age and is
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people with CFS/ME is estimated to decline by 37% in the
household and by 54% in the labor force [11]. The resulting
annual economic loss is of a significant magnitude estimated at
$20,000 for each individual. With at least 1 million persons
affected, the US national loss from CFS/ME greatly exceeds that
estimated for other illnesses such as infectious and parasitic
diseases ($10 billion), digestive system illnesses ($8.4 billion), and
nervous system disorders ($6.4 billion) [11]. These productivity
estimates do not include the significant health care costs for
persons with CFS/ME, nor do they address the negative impact
on the individual and family that results from the severe
debilitation and reductions in quality of life.
With no approved drug therapy available, treatment is aimed at
symptom relief and improved ambulatory function [12]. These
include over the counter and off-label prescription drugs,
behavioral modifications, and graded exercise therapies. The
rationale for the initial trials with rintatolimod (Poly I:C12U) in
CFS/ME were based on its recognized antiviral and immuno-
modulatory properties and as an inducer of interferon [13]. These
properties are mediated by its activity as a selective toll-like
receptor 3 (TLR-3) agonist in the induction of innate immune
responses [14]. Toll-like receptors, as primordial transmembrane,
pattern recognition receptors, trigger alarm signals against
invading pathogens by modulating cytokine cascades. The initial
success of open-label trials provided the basis for the double-blind,
placebo controlled Phase II [15] and the current Phase III clinical
trial as well as its FDA designation as an Orphan Drug for CFS
and an FDA authorized treatment protocol for use of rintatolimod
in CFS.
Cardiopulmonary exercise tolerance (ET) testing is an objective
measurement of treatment efficacy for fatigue and is accepted as a
regulatory standard for drugs ameliorating exertional fatigue by
exhibiting an average improvement of at least a 6.5% in intra-
group, placebo-adjusted ET [16–19]. The Phase III multi-center,
double-blind, placebo controlled trial reported here uses ET as its
primary endpoint and the reduction in drug usage for symptom
relief as one of several secondary endpoints in the evaluation of
rintatolimod in the treatment of CFS/ME.
Methods
Trial design
This study was a prospective, double-blind, Phase III trial with
equal parallel cohorts conducted at 12 centers in the U.S. to
evaluate the safety and efficacy of rintatolimod in CFS. The
protocol for this trial and supporting CONSORT checklist are
available as supporting information; see Checklist S1 and Protocol
S1. The design of the study, including endpoint, and the statistical
method used to define efficacy were all reviewed by the FDA prior
to receipt of FDA authorization for the initiation of the study. The
objective of this study was to compare in a blinded, randomized,
placebo-controlled trial, changes in exercise tolerance, concomitant
medication usage and other quality of life endpoints including safety
parameters in patients with CFS/ME treated with rintatolimod vs.
placebo. The inclusion and exclusion criteria for study enrollment is
detailed in Table S1 and meets both the original [1] and revised [2]
CDC clinical definitions of CFS. All patients gave written informed
consent and had a diagnosis of CFS $12 months resulting in
significant debilitation (KPS score of 40–60). A list of Principal
Investigators in the CFS AMP-516 Study Group is shown in Table
S2 along with the 12 study sites and Institutional Review Boards.
This study was initiated on 12/17/98, and ended following full
enrollment on 8/16/04 when the last patient completed.
Patients were stratified according to their treadmill duration
(#9 minutes vs. .9 minutes) and randomized to receive either
rintatolimod (n=117) or placebo (n=117). Following a 200 mg
IV dose or equal volume of placebo (physiological saline) twice
weekly for two weeks, 400 mg was administered IV twice weekly
versus placebo IV to 234 randomized patients with severe CFS for
a total of 40 weeks (Stage 1). At the conclusion of Stage 1, the blind
was continued and patients randomized to placebo were crossed-
over to rintatolimod, while the original rintatolimod arm of the
study continued on rintatolimod for 24 weeks (Stage 2). The
primary endpoint was ET on a treadmill (Trackmaster TM 225,
Full Vision, Inc., Newton, KS) with ECG monitoring performed
by a team of exercise physiology specialists who traveled to each of
the trial sites (Workwell Physiology Services, Inc., Ripon, CA).
Secondary endpoints included changes in the use of concomitant
medications to treat CFS/ME symptoms, Karnofsky Performance
Score (KPS) (Table S3), Activities of Daily Living (ADL), and the
Vitality and General Health Perceptions subscales from the Short
Form 36-Health Survey (SF-36).
Quality assurance of clinical and laboratory data and
randomization
Rintatolimod (AmpligenH) used in this study was manufactured
in accordancewith Good Manufacturing Practice (GMP) and tested
under Good Laboratory Practice (GLP) and Good Clinical Practice
(GCP) guidelines. Prior to the initiation of the study, vials of active
and placebo drug were prepared and labeled with a unique
allocation number. After providing informed consent and meeting
the entrance criteria, patients were first stratified by duration of ET,
and then randomized and assigned to receive an allocation number
that tied back to the blinded drug supply provided for the study. At
the site and patient level, only the allocation number was known,
which provided no insight to the randomization assignment of the
study drug. The patient randomization schedules utilized a
permuted block design size of 4 and were provided by an
independent group, Simirex, Inc., Mt. Laurel, NJ. Knowledge of
randomization schedules and patient assignments was restricted to
the individuals responsible for preparing and packaging the study
medication;none oftheseindividuals hadanyotheroperationalrole
in the study. Unblinding of the study occurred following final field
audits for data accuracy and database lock.
Exercise tolerance (ET) testing
Patients underwent treadmill ET testing according to a
standardized protocol (Table S4). Subjects rated their perceived
exertion, generally considered to be a reliable indicator of fatigue
[20], using the Borg Scale and progressed through stages
successively until they could no longer continue. The ET result
was recorded as the total time on the treadmill. In order to reduce
variation in test results, each site used the same make and model of
treadmill (Trackmaster TM 225, Full Vision, Inc., Newton,
Kansas USA) and the same group of exercise physiologists
traveled to each site to administer the treadmill test throughout
the study. Treadmills were calibrated on the day of each test for
speed and inclination. Two treadmill exercise tests were performed
during baseline. If the two baseline tests differed by more than
610% of the maximum duration from their mean value, a third
test was performed. When three baseline tests were performed, the
two closest tests were used for data analysis of ET.
Sample size
The sample size for this clinical investigation was based on
detecting a difference in the intra-patient changes in ET (seconds)
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a type 1 error rate of 5%. With a minimum of 100 patients
enrolled per treatment arm, a mean difference between the active
treatment arm and placebo arm equivalent to 40% of the common
standard deviation would have 80% power to detect a difference
using a 2-tailed analysis with an alpha of 5%.
Statistical analysis
Data analyses used SAS (Version 8.2 and 9.1) statistical
software. All statistical analyses were two-sided. The primary
endpoint (intra-patient changes in treadmill duration, week
40 minus baseline) was analyzed using a one-factor (treatment
assignment) analysis of covariance test (ANCOVA) with the mean
of two baseline treadmill ET serving as the covariate. Although the
design of the study considered repeated measurements on the
patients over time, the statistical model for evaluating efficacy was
predicted on a landmark analysis based on the intra-patient
changes at week 40. The 2-sample t-test was used to compare
baseline ET between the two randomized treatment groups; the
intra-group changes (also known as ‘‘within group changes’’) in ET
from baseline to week 40 were analyzed using a paired-difference
t-test. The proportion of patients who achieved a 25% to 50%
increase in ET at week 40 (intra-patient changes or within subject
changes) was compared between randomized treatment groups
using a two-tailed chi-square test in a continuous responder
analysis, calculated using 5% increments from $25% improve-
ment to $50% improvement. Secondary endpoints were analyzed
based on the distribution of the dependent variable. The normality
of the distributions was examined using the Shapiro-Wilk test.
The intent-to-treat (ITT) population included all patients who
received study drug and performed the ET study parameter at
least once during the treatment phase. The last ET observation
was used for patients who failed to complete the week 40 visit. A
completer group, consisting of all patients who competed the 40
weeks of Stage 1, was also pre-specified. All analyses were
conducted using the statistical software from the SAS Institute
(Cary NC).
Results
Demographic and other baseline characteristics
Of the 234 patients with CFS/ME admitted to the study, an
equal number (n=117) were randomized to each study arm,
rintatolimod versus placebo (Figure 1). The two study arms were
well balanced. There was no statistically significant difference with
regard to age (43.4 versus 43.5 years), duration of CFS symptoms
(9.6 versus 9.7 years), time from diagnosis (5.9 versus 5.9 years),
percentage female gender (67.5 versus 77.8), or body weight (167
versus 166 pounds) between the rintatolimod and placebo cohorts,
respectively (Table S5).
Primary endpoint analysis
The primary efficacy endpoint of the study was improvement in
treadmill ET at week 40. One hundred ninety four patients (194)
completed all 40 weeks of Stage 1. In addition, seven rintatolimod
and seven placebo patients, who discontinued the study,
completed a treadmill ET test following initial dosing and were
included in the ITT analysis. The reasons for discontinuation are
presented in Figure 1. An analysis of the primary endpoint,
treadmill ET, at 40 weeks in the ITT group is shown in Table 1A.
By week 40, the rintatolimod cohort (n=100) had a mean change
increase in ET of 96 seconds to 672, corresponding to a group
mean increase of 16.6% and an intra-patient mean increase of
36.5%. In contrast, the placebo group (n=108) increased ET by
28 seconds to 616 corresponding to an intra-group mean increase
of 4.8% and an intra-patient mean increase of 15.2%. The
placebo-adjusted intra-group and intra-patient increases in the
rintatolimod ITT cohort were 11.8% and 21.3%, respectively
(p=0.047). For the patients who completed all 40 weeks (Table 1B)
of the study (n=194), mean baseline ET was 583 seconds for the
rintatolimod cohort (n=93) compared to 587 seconds for the
placebo group (n=101). At week 40, the rintatolimod patients had
increased mean ET by 108 seconds (18.6%) to 691 compared to
an increase of 27 seconds (4.6%) to 614 in the placebo cohort. The
placebo-adjusted, intra-group and intra-patient increases were
14.0% and 24.6%, respectively.
The intra-patient change in ET relates to the individual patient
responses. The statistic is utilized to determine the proportion of
rintatolimod versus placebo patients that increased ET by $25%
and $50%. The placebo-adjusted mean intra-treatment group
change of 11.8% is important for showing efficacy. A pre-defined
minimum of 6.5% increase in mean intra-treatment group ET was
required in the protocol to show efficacy. Table S8 provides a
comparison of the intra-group ET benefit achieved by rintatolimod
compared to current medical and regulatory standards of care for
cardiotropicdrugsprovidingbenefitforexertionalfatigue symptoms.
At 40 weeks, the difference in improvement in ET for the
rintatolimod versus placebo cohorts in the pre-specified completer
and ITT groups was statistically significant (p=0.019 and 0.047,
respectively) using an analysis of covariance model. A paired-
difference t-test for analysis of the intra-patient difference from
baseline provided additional evidence that rintatolimod produced
a significant increase in ET for patients debilitated with CFS/ME.
Both the completer and ITT populations improved ET signifi-
cantly (p,0.001) compared to the placebo cohorts (p$0.198).
The effect of a pre-specified dose modification analysis was
performed by exclusion of patients in the ITT population with
significant dose reductions, defined as a combined total of 20
missed doses or dose reductions of at least 50%. Table 1C
demonstrates that when patients with significant dose reductions
were excluded, the placebo-adjusted intra-patient mean improve-
ment in ET was 28% (p=0.022) with ET in the rintatolimod arm
significantly enhanced (p,0.001) from baseline compared to the
placebo arm (0.263).
Additional evidence supporting the efficacy of rintatolimod in
CFS/ME was provided by an ad hoc analysis of the frequency
distribution of percent improvement in ET from baseline to week
40 in the rintatolimod versus placebo cohorts (Table 1D). The
proportions of patients in the ITT population with increases in ET
from baseline to week 40 of at least 25% and of at least 50% were
1.7 and 1.9-fold greater for patients randomized to rintatolimod
than placebo, 39% versus 23% (p=0.013) and 26% versus 14%,
respectively (p,0.028). A continuous responder analysis, calculat-
ed using 5% increments from $25% improvement to $50%
improvement revealed a significant difference at 40 weeks in favor
of the patients who received rintatolimod compared tp placebo.
The proportion of patients with decreases in ET from baseline to
week 40 of at least 25% were not statistically significantly different
between the rintatolimod versus placebo cohorts, 17% versus
19%, respectively (p=0.76).
Although separate analyses of the two baseline ET stratification
subgroups was not powered adequately, the results demonstrated a
medically significant increase in ET in both subgroups. Table 1E
demonstrates that medically significant, placebo-adjusted en-
hancement of treadmill ET of 15% and 31% was seen in the
patients stratified to the high and low baseline performance
cohorts, respectively. Stage 2 results support the conclusions of
Stage 1. The Stage I double-blinded status was maintained in
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rintatolimod achieved a mean intra-patient percent improvement
in ET of 39% (p=0.040) in 24 weeks, while the original
rintatolimod cohort maintained their improvement in ET
(Table 2).
Secondary endpoint analysis
A variety of secondary endpoints were studied for evidence of
efficacy. These endpoints were discussed and agreed upon with the
FDA prior to the initiation of the study. Concomitant medications
were recorded on the case report forms (CRF) with a
Figure 1. Flow Diagram of Study Patients.
doi:10.1371/journal.pone.0031334.g001
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taken to alleviate CFS/ME-related symptoms. Subjects were
neither counseled or encouraged to discontinue medications
before starting study drug. Table 3 illustrates the change in
concomitant drug usage for the relief of CFS symptoms at the
conclusion of Stage 1. Rintatolimod treatment was associated with
a significant reduction in drug usage at 40 weeks as compared to
placebo in both analyses of patients who completed 40 weeks of
treatment (p=0.010) and the ITT population (p=0.015) taking
CFS/ME-palliative drugs, and the total completer (p=0.029) and
ITT populations (p=0.048). Table S9 shows the most frequently
used drug categories and examples of each.
Significant changes (p,0.01) from baseline in secondary
performance endpoints were observed in KPS, ADL, and vitality
scores for the patients receiving rintatolimod during Stage 1
(Table 4). Although the placebo cohort did not improve the
median KPS score, the Wilcoxon signed rank analysis indicated a
significant shift in individual scores. Similarly, a significant change
was seen with regard to general health perceptions for the placebo
cohort, but not for the rintatolimod cohort, despite having the
same baseline and week 40 median scores. During Stage 2,
additional support for the efficacy of rintatolimod in CFS/ME was
seen (data not shown). Analysis of the ITT population showed that
median KPS increased from 50 to 60 (p,0.001) and mean ADL
improved from 71.3 to 72.4 (p=0.04), no significant change in
vitality or general health perceptions scores was seen during Stage
2.
Safety assessment
During Stage 1, 99% of rintatolimod patients reported at least
one adverse event (AE) compared to 97% in the placebo cohort
(Table 5). Four AEs (flu-like syndrome, chills, vasodilatation and
Table 1. Analysis of the Effect of Rintatolimod on the Primary Endpoint, Exercise Tolerance (ET).
A. Increase in Exercise Treadmill Duration with Rintatolimod in CFS Patients (Intent-to-Treat)
Study Interval Mean (SD) Exercise Duration (Seconds) Percent Increase from Baseline
1
p-value
Rintatolimod (n=100) Placebo (n=108) Rintatolimod (n=100) Placebo (n=108)
Baseline 576 (257.5) 588 (234.4) - - 0.729
2
Week 40 672 (314.1) 616 (286.7) 36.5 15.2 0.047
3
p-value
4 -- ,0.001 0.198
B. Increase in Exercise Treadmill Duration with Rintatolimod in CFS Patients (Completer Population)
Study Interval Mean (SD) Exercise Duration (Seconds) Percent Increase from Baseline
1
p-value
Rintatolimod (n=93) Placebo (n=101) Rintatolimod (n=93) Placebo (n=101)
Baseline 583 (254.7) 587 (237.3) - - 0.908
2
Week 40 691 (311.4) 614 (291.2) 40.2 15.6 0.019
3
p-value
4 -- ,0.001 0.244
C. Increase in Exercise Treadmill Duration with Rintatolimod in CFS Patients without Significant Dose Reductions (Intent-to-Treat)
Study Interval Mean (SD) Exercise Duration (Seconds) Percent Increase from Baseline
1
p-value
Rintatolimod (n=83) Placebo (n=98) Rintatolimod (n=83) Placebo (n=98)
Baseline 581 (256.2) 590 (235.3) - - 0.813
2
Week 40 690 (308.2) 616 (291.4) 43.0 15.0 0.022
3
p-value
4 -- ,0.001 0.263
D. Frequency Distribution of Percent Change from Mean Baseline Exercise Treadmill Duration at Week 40 (Intent-to-Treat)
Improvement from Mean Baseline Exercise Treadmill Duration Rintatolimod (n=100) Placebo (n=108) p-value
5
At least 25%, n (%) 39 (39) 25(23) 0.013
At least 50%, n (%) 26 (26) 15 (14) 0.028
E. Effect of Baseline ET on Week 40 ET (Intent-to-Treat)
Mean (SD) Exercise Duration Mean (seconds)
% Gain
Rintatolimod
over Placebo
1 p-value
3
Baseline ET Strata (Minutes) #9 Drug (n=40) #9 Placebo (n=42) .9 Drug (n=60) .9 Placebo (n=66) #9 .9 #9 .9
Baseline 321 (153.3) 353 (144.6) 747 (148.3) 738 (137.7)
Week 40 450 (284.2) 446 (264.6) 820 (237.3) 725 (245.9) 31.0 15.0 0.517 0.034
1Mean intra-patient percent improvement.
2Student’s t-test comparing mean baseline ET between treatment groups.
3Analysis of covariance (ANCOVA) with baseline as a covariate comparing the mean ET change from baseline within each treatment group.
4Paired t-test comparing whether the change from baseline is equal to zero within each treatment group.
5Probability that a difference between treatment groups exists using the chi-square test.
doi:10.1371/journal.pone.0031334.t001
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compared to the placebo cohort (p,0.05, Fisher’s exact test).
These symptoms were generally mild or moderate in severity.
There was no statistically significant difference in the frequency
of injection site reactions between the two study groups (see
Table S6 for the frequency of adverse events). The frequency of
serious AEs during Stage 1 was not significantly different
between the two study arms. No serious AEs were definitely
related to study drug. Table S7 summarizes the serious AEs
during Stage 1. There were no clinically significant differences
between the two treatment cohorts with regard to the number or
percentage of patients with AEs in Stage 2. There were three
serious AEs in each study arm judged by the site PI as not related
(n=5) or remotely related (n=1) to the study drug. There were
two deaths in Stage 2, neither in the opinion of the principal
investigators at the clinical sites was related to study drug. A 59
year-old male died of respiratory failure related to pneumonia
and lung disease, a pre-existing condition. The other death
occurred in a 40 year-old male, who was shooting a firearm at
motor vehicles and committed suicide when confronted by
police. The investigator concluded that the death was related to
pre-existing conditions of CFS/ME related depression and a
history of violent behavior. Neither of these pre-existing
conditions disqualified entry into the trial. Notably the three
most prevalent causes of death in CFS/ME patients are heart
failure, suicide and cancer [21,22]. Also, these studies typically
Table 2. Mean/Median Baseline and Mean/Median Change from Baseline in Exercise Treadmill Duration (seconds) at Week 24
(Stage 2) (ITT Population).
Treatment Cohorts
Prior Double-Blinded Randomized Treatment (Stage 1)
Q
Double-Blinded Cross-over Treatment (Stage 2)
Exercise Tolerance (ET) Test Parameter
Rintatolimod (Stage 1)
Q
Rintatolimod (Stage 2)
(n=72)
Placebo (Stage 1)
Q
Rintatolimod (Stage 2)
(n=90)
Mean (SD) Median Mean (SD) Median
Baseline ET (seconds)
1 706 (308) 726 626 (291) 638
ET at End of Stage 2 (seconds) 696 (323) 732 669 (288) 665
ET Difference (seconds) 210.4 (160.36) 14.0 43.1 (198.26) 46.0
Percent ET Improvement
2 22.9 1.7 39.0 8.9
p-value
3 0.58 0.69 0.04 0.02
1Baseline of Stage 2 is the last non-missing Stage 1 value (last observation carried forward [LOCF]).
2Mean intra-patient percent improvement.
3p-value for the mean is from a paired t-test; p-value for the median is from the Wilcoxon signed rank test.
doi:10.1371/journal.pone.0031334.t002
Table 3. Effect of Rintatolimod (PolyI:C12U) on the Use of Concomitant Medications for the Relief of CFS Symptoms (Stage I).
Number (%) of Patients
Direction of Change
1 Rintatolimod Placebo p-value
2
1. Change from initial medication use to end of study use (intent-to-treat)
Decrease 68 (68) (n=100) 59 (55) (n=108) 0.048
No decrease 32 (32) (n=100) 49 (45) (n=108) 0.048
2. Change from initial medication use to end of study by the cohort who used concomitant medications (intent-to-treat)
Decrease 68 (72) (n=94) 59 (56) (n=106) 0.015
No decrease 26 (28) (n=94) 47 (44) (n=106) 0.015
3. Change from initial medication use to end of study use in patients completing 40 weeks
Decrease 64 (69) (n=93) 54 (53) (n=101) 0.029
No decrease 29 (31) (n=93) 47 (47) (n=101) 0.029
4. Change from initial medication use to end of study by the cohort who used concomitant medications in patients completing 40 weeks
Decrease 64 (73) (n=88) 54 (55) (n=99) 0.010
No decrease 24 (27) (n=88) 45 (45) (n=99) 0.010
1Daily average of the number of concomitant medications used during the first 4 weeks of study compared to the daily average of the number used during the final 4
weeks of study.
2Chi-square test.
doi:10.1371/journal.pone.0031334.t003
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treated in this clinical trial of rintatolimod.
There were no clinically significant changes from baseline
hematology, chemistry, or coagulation laboratory tests, all mean
values remained within the normal range. No patient discontinued
secondary to a grade 3 or 4 laboratory toxicity. There were no
statistically significant differences in physical exam findings, or
post-infusion vital signs.
Discussion
CFS/ME patients exhibiting both the Holmes [1] and Fukuda
[2] diagnostic criteria were selected for this study. The primary
endpoint of efficacy, improvement in ET, achieved statistical
significance by several analytical methods applied to the ITT
cohort. The intra-patient placebo-adjusted enhancement in mean
ET at Week 40 was 21.3% (p=0.047). Correction for patients
with significant missed doses or dose reductions improved mean
intra-patient ET enhancement to 28% (p=0.022). The propor-
tions of patients in the ITT population with changes from mean
baseline ET duration at week 40 of at least 25% and of at least
50% were 1.7 and 1.9-fold greater for subjects randomized to
rintatolimod than placebo, 39% versus 23% (p=0.016) and 26%
versus 14% (p=0.036), respectively. At week 40, the ITT
population randomized to rintatolimod had a placebo-adjusted
mean intra-treatment group change from baseline ET of 11.8%,
1.8-fold higher than pre-defined in the protocol as the minimum
6.5% required to show efficacy (16–19). Table S8 provides a
comparison of the intra-group benefit achieved by rintatolimod to
current medical and regulatory standards of care for cardiotropic
drugs providing benefit for exertional fatigue symptoms.
There is no specific treatment for CFS/ME and patients utilize
a large number of drugs in an attempt to alleviate the debilitating
symptoms of the illness. Decreases in concomitant medication
usage is an objective measure of the effect of rintatolimod on the
symptoms of CFS/ME. Rintatolimod was associated with a
statistically significant reduction in the use of concomitant
medications used to help treatment symptoms to CFS/ME
relative to placebo: 68% of patients receiving rintatolimod
decreased use of concomitant medications related to CFS versus
55% of subjects receiving placebo (P=0.048). Other secondary
endpoints provided additional evidence of efficacy during Stage 1
and the blinded Stage 2 cross-over. The data from this Phase III
trial, moreover, supports an earlier double-blinded, controlled
Phase II trial [15], which also demonstrated a greater mean intra-
patient ET improvement with rintatolimod compared to placebo
(31% vs. 16% (p=0.01)). The decrease in concomitant medication
usage associated with rintatolimod treatment has been reported
previously to decrease the prolonged cardiac QT intervals induced
by many of the drugs used by patients with CFS/ME to alleviate
the symptoms of CFS/ME [23].
Rintatolimod was generally well-tolerated in patients with CFS/
ME. The total number of AEs were statistically equivalent
between cohorts, although patients receiving rintatolimod had
an increased incidence in four AEs (flu-like syndrome, chills,
vasodilatation and dyspnea) of usually mild severity. Two deaths,
Table 4. Secondary Performance Endpoint Improvements in Stage 1.
Rintatolimod Placebo
Secondary Performance Endpoint Baseline Week 40 p-value
1 Baseline Week 40 p-value
1
Karnofsky Performance Score (KPS) 50 55 ,0.01 50 50 ,0.01
Activities of Daily Living (ADL) 68.1 72.4 ,0.01 68.7 69.4 ns
2
Vitality Score (SF-36) 5.0 10.0 ,0.01 10.0 10.0 ns
2
General Health Perception (SF-36) 20 20 ns
2 20 25 ,0.01
1p-value derived from a Wilcoxon signed rank test comparing whether the median change from Baseline is equal to 0 within each treatment group.
2ns=not significant, p.0.05.
doi:10.1371/journal.pone.0031334.t004
Table 5. Safety- Adverse Events (AEs) of Rintatolimod (PolyI:C12U).
Rintatolimod (n= 117) Placebo (n=117)
A. Stage 1: AEs During 40 Weeks of Drug Exposure Number of Patients % of Patients Number of Patients % of Patients
Patients with $1 AE 116 99.1 113 96.6
All AEs with p#0.05
Flu-like syndrome 62 53.0 46 39.3
Chills 26 22.2 11 9.4
Vasodilatation 25 21.0 11 9.4
Dyspnea 14 12.0 4 3.4
Patients with $1 Serious AE 12 10 6 5
B. Stage 2: AEs During 24 Weeks Cross-over Study Rintatolimod R Rintatolimod (n=90) Placebo R Rintatolimod (n=100)
Patients with $1 AE 86 95.6 98 98.0
Patients with $1 Serious AE 3 3.3 3 3.0
doi:10.1371/journal.pone.0031334.t005
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treatment. No significant differences were observed between
rintatolimod and placebo in mean hematological, or blood
chemistry parameters.
A potential limitation of this trial is that only severely debilitated
cases of CFS were enrolled. All patients had a diagnosis of CFS for
at least 12 months and a baseline KPS score of 40–60. Therefore,
the findings may not be relevant for patients with CFS disease of a
lesser severity. A potential source of bias exists since a commercial
entity, Hemispherx Biopharma, Inc. funded and conducted this
trial using independent investigators. This concern is mitigated
since this study remained blinded to all Hemispherx clinical trial
staff involved with the study until data base lock and the clinical
data and statistical analysis were reviewed and audited by the
FDA. This audit included a comparison if the data utilized for the
statistical analysis versus the data contained in source documents
at the investigator sites.
Differential gene expression in peripheral blood of CFS/ME
patients has been reported by a number of investigators using
DNA microchip analysis [24–34]. Recently, rigorous patient
selection and a microchip that surveys the entire human genome
coupled with qPCR gene validation has provided a more complete
appreciation of the gene expression profiles that occur in CSF [9–
10]. A complex array of differential gene expression can be
categorized into functional subsets relating to responses to
infection, immunity, inflammation, apoptosis, neurological func-
tion, and cancer [10]. Many of these differential gene responses
are consistent with the large number of infectious agents linked
with CFS/ME as well as the altered immune responses and variety
of signs and symptoms observed with the disease. For example,
eIF4G1 is an eukaryotic mitochondrial translation factor utilized
in replication by a variety of viruses including the enteroviruses
implicated in the pathogenesis of CFS/ME [9,35]. EIF4G1
variant 5 (GenBank:NM_004953) is upregulated in CFS/ME
suggesting a physiological response to viral replication as well as a
gene variant favoring pathogen persistence.
Prior to this report, no treatment had been demonstrated to be
active in multiple randomized controlled clinical trials. The
observed activity of rintatolimod in CFS/ME provides a rational
intervention in this complex, multi-factorial disease. Rintatolimod
is an activating ligand (dsRNA) for TLR3, which is a first line
defense mechanism essential in the induction of innate immunity.
Although the mechanism of action of rintatolimod in CFS is
unknown, certain genes may be modulated by rintatolimod
including those for metabolic enzymes, antiviral response
elements, and immune mediators. Subsequent modulation of
host defense responses may depend on transient expression of
multiple genes and modulation of a number of enzymes regulated
by TLR 3 activation. Among the hundreds of upregulated genes
triggered by this process [36] are the interferons with broad anti-
viral activities mediated by interferon’s own upregulation of anti-
viral genes including 2–59 adenylate synthetase and protein
kinase (p68) activated by rintatolimod [37]. The availability of
diagnostic assays, based on gene expression profiles, may provide
a prognostic genetic signature that will predict response, as well as
the opportunity to develop synergistic combinations of rintato-
limod and other agents to expand the therapeutic effect in this
debilitating disease. The current study more clearly establishes
the safety profile of rintatolimod. Other TLRs including those for
TLR4 and TLR9 are under development for human use. Their
safety, however, based on clinical trials has been questioned
based on safety issues, pharmacokinetics, and biodistribution
[38]. The safety profile of rintatolimod is likely related to the
exclusive use of the TRIF intracellular signaling pathway [39] as
well as the restriction of rintatolimod as a TLR3 agonist, a
property not exhibited by the toxic TLR3 ligand, Poly I:C
[19,40]. The pathway of TLR3 induction of innate immunity is
unique among the TLRs by its exclusive utilization of TRIF as
the molecular mediator of NF-kB, IRF-3/IRF-7 transcription
factors [39]. All the other TLRs utilize a MyD88/TiRAP adapter
mediated pathway. The safety profile and unique innate immune
stimulating properties of rintatolimod provides strong motivation
to assess its potential role in microbial and cancer vaccines.
Rintatolimod activates dendritic cells and potentiates both
humoral and cell-mediated responses [40]. For example,
Japanese investigators have demonstrated that rintatolimod has
powerful adjuvant activity when coupled with various influenza
vaccines including highly pathogenic avian influenza virus
(HPAIV) [41–43]. The Japanese government has invested
significant effort in providing preclinical data in support of
clinical trials of rintatolimod for seasonal and H5N1 HPAIV
vaccines.
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